Current Assets
Cash & Equivalents
Bristol-Myers Squibb Cash & Equivalents decreased by 6.2% to $9.57B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 12.0%, from $10.88B to $9.57B. Over 5 years (FY 2020 to FY 2025), Cash & Equivalents shows a downward trend with a -7.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryLiquidity
SignalHigher is better
VolatilityModerate
First reportedQ4 2012
Last reportedQ1 2026Apr 30, 2026
How to read this metric
Higher levels indicate strong liquidity and financial flexibility; lower levels may signal potential cash flow issues.
Detailed definition
This represents the most liquid assets held by the company, including cash on hand, demand deposits, and short-term inve...
Peer comparison
A universal metric for assessing a company's immediate financial health.
Metric ID:
cash_and_equivalentsHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $11.40B | $13.88B | $14.32B | $12.58B | $10.96B | $7.96B | $9.33B | $9.05B | $8.43B | $7.57B | $11.46B | $9.33B | $6.29B | $7.89B | $10.35B | $10.88B | $12.60B | $15.73B | $10.21B | $9.57B |
| QoQ Change | — | +21.8% | +3.1% | -12.1% | -12.9% | -27.4% | +17.2% | -3.0% | -6.9% | -10.2% | +51.5% | -18.6% | -32.6% | +25.4% | +31.1% | +5.1% | +15.9% | +24.8% | -35.1% | -6.2% |
| YoY Change | — | — | — | — | -3.8% | -42.7% | -34.9% | -28.1% | -23.1% | -4.9% | +22.9% | +3.1% | -25.3% | +4.3% | -9.8% | +16.6% | +100.2% | +99.3% | -1.3% | -12.0% |
Range$6.29B – $15.73B
CAGR-3.6%
Avg YoY Growth+3.8%
Median YoY Growth-4.4%
Current Streak2 quarters decline
Cash & Equivalents at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's cash & equivalents?
- Bristol-Myers Squibb (BMY) reported cash & equivalents of $9.57B in Q1 2026.
- How has Bristol-Myers Squibb's cash & equivalents changed year-over-year?
- Bristol-Myers Squibb's cash & equivalents decreased by 12.0% year-over-year, from $10.88B to $9.57B.
- What is the long-term trend for Bristol-Myers Squibb's cash & equivalents?
- Over 5 years (2020 to 2025), Bristol-Myers Squibb's cash & equivalents has grown at a -7.4% compound annual growth rate (CAGR), from $14.97B to $10.21B.
- What does cash & equivalents mean?
- Cash and highly liquid assets that can be converted to cash within 90 days.